4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.7% After Insider Selling

4D Molecular Therapeutics, Inc. (NASDAQ:FDMTGet Rating) shares traded down 3.7% during trading on Monday following insider selling activity. The stock traded as low as $19.56 and last traded at $19.56. 8,210 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 255,086 shares. The stock had previously closed at $20.31.

Specifically, insider Scott Bizily sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $22.79, for a total value of $136,740.00. Following the completion of the transaction, the insider now directly owns 2,482 shares of the company’s stock, valued at $56,564.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $22.79, for a total value of $136,740.00. Following the completion of the sale, the insider now owns 2,482 shares in the company, valued at $56,564.78. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO David Kirn sold 10,899 shares of the company’s stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $20.03, for a total value of $218,306.97. Following the sale, the chief executive officer now owns 1,902,224 shares of the company’s stock, valued at approximately $38,101,546.72. The disclosure for this sale can be found here. Insiders sold 49,832 shares of company stock valued at $1,131,936 over the last three months. 11.22% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on FDMT shares. Bank of America upped their price target on 4D Molecular Therapeutics from $15.00 to $25.00 in a research note on Monday, November 14th. Evercore ISI upped their price target on 4D Molecular Therapeutics from $32.00 to $45.00 in a research note on Monday, November 14th. HC Wainwright began coverage on 4D Molecular Therapeutics in a research note on Friday, November 18th. They set a “buy” rating and a $36.00 price target for the company. The Goldman Sachs Group upgraded 4D Molecular Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $12.00 to $68.00 in a research report on Tuesday, November 15th. Finally, SVB Leerink increased their price objective on 4D Molecular Therapeutics from $10.00 to $11.00 and gave the stock a “market perform” rating in a research report on Thursday, November 10th.

4D Molecular Therapeutics Price Performance

The company has a 50-day simple moving average of $21.99 and a 200-day simple moving average of $13.47.

4D Molecular Therapeutics (NASDAQ:FDMTGet Rating) last posted its earnings results on Tuesday, November 8th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.06. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.70 million. 4D Molecular Therapeutics had a negative return on equity of 36.94% and a negative net margin of 5,331.88%. As a group, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at $196,000. Eagle Health Investments LP boosted its stake in shares of 4D Molecular Therapeutics by 97.9% during the second quarter. Eagle Health Investments LP now owns 261,423 shares of the company’s stock valued at $1,825,000 after acquiring an additional 129,333 shares during the last quarter. Alps Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at $134,000. Point72 Asset Management L.P. acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at $2,404,000. Finally, New York State Common Retirement Fund boosted its stake in shares of 4D Molecular Therapeutics by 102.6% during the third quarter. New York State Common Retirement Fund now owns 19,661 shares of the company’s stock valued at $158,000 after acquiring an additional 9,956 shares during the last quarter. Institutional investors and hedge funds own 79.94% of the company’s stock.

About 4D Molecular Therapeutics

(Get Rating)

4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.

Featured Stories

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.